openPR Logo
Press release

HIV Drugs Market Share, Trends, Size, Major Players And Forecast To 2033

04-17-2024 10:08 AM CET | Health & Medicine

Press release from: The Business Research Company

HIV Drugs Market

HIV Drugs Market

The hiv drugs market size has grown steadily in recent years. It will grow from $33.82 billion in 2023 to $35.33 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increased government support and initiatives, rise in healthcare expenditure, increase in hiv research and development spending, increased incidence of hiv infection, rise in awareness and economic growth in emerging markets.

The hiv drugs market size is expected to see steady growth in the next few years. It will grow to $41.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to increased government support and initiatives, rise in healthcare expenditure, increase in hiv research and development spending, increased incidence of hiv infection, rise in awareness and economic growth in emerging markets. Major trends in the forecast period include investing in 3d bioprinting technology, new product innovations, developing multi-class combination products for hiv treatment and investing in strategic collaborations and agreements.

Market Overview -
HIV drug refers to an antiretroviral drug that is frequently used to treat HIV. HIV medications prevent the spread of the human immunodeficiency virus (HIV) or other retroviruses in the body. HIV can cause AIDS if it is not treated (acquired immunodeficiency syndrome). Currently, there is no cure that works well.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

Repurposing Hiv Drugs For Covid-19 Treatment
The novel coronavirus outbreak has augmented the growth of the global HIV drug market. HIV drugs are repurposed to treat Covid 19 infections. Currently, several countries are evaluating and using antiretroviral drugs (For instance, lopinavir boosted with ritonavir (LPV/r)), for treating coronavirus infection.

Competitive Landscape -
Major companies operating in the hiv drugs market report are Gilead Sciences Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Mylan N.V., Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China's National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, Alfa Rio Química Ltda., Globe Quimica S/A, Nortec Química S.A., AstraZeneca, Zion Medical, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

Advancements In Multi-Class Combination Products
The antiretroviral drugs market is increasingly implementing multi-class combination products for the treatment of antiretroviral therapy. Combination drugs combine multiple medications into one drug form. Examples of multiclass combination drugs or single-tablet regimens (STRs) include both NRTIs and NNRTIs: doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo). Based on drug class, drugs are segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Others. Multi-class Combination Products are the rising burden of HIV and new drug approval. According to WHO, In 2021, 1.5 million [1.1-2.0 million] people contracted HIV, and 650 000 [510 000-860 000] people died from HIV-related causes. Many companies are focusing on developing breakthrough products for the treatment through antiretroviral drugs to maintain their competitive advantage and penetrate new regional markets.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

Key Segments -

The hiv drugs market covered in this report is segmented -

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT's), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types
2) By Administration: Oral, Parenteral
3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV Drugs Market Share, Trends, Size, Major Players And Forecast To 2033 here

News-ID: 3466924 • Views:

More Releases from The Business Research Company

Segment Evaluation and Major Growth Areas in the Personalized Testing and Supplements Market
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future. Market Valuation and Expansion Forecast for Personalized Testing
Top Players and Market Competition in the Skin Microbiome Industry
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry. Projected Expansion in the Skin
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market Landscape
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory. Steady Growth Expected in Upadacitinib Market Size Through 2029 The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Market
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field. Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics

All 5 Releases


More Releases for HIV

HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792 This latest report researches the industry structure, sales, revenue,
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways